- Home
- CHRS vs OPTN Comparison
CHRS vs OPTN Comparison
Compare CHRS & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OPTN
- Stock Information
- Founded
- CHRS 2010
- OPTN 2010
- Country
- CHRS United States
- OPTN United States
- Employees
- CHRS N/A
- OPTN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- OPTN Health Care
- Exchange
- CHRS Nasdaq
- OPTN Nasdaq
- Market Cap
- CHRS 100.9M
- OPTN 99.7M
- IPO Year
- CHRS 2014
- OPTN 2017
- Fundamental
- Price
- CHRS $1.10
- OPTN $0.37
- Analyst Decision
- CHRS Strong Buy
- OPTN Strong Buy
- Analyst Count
- CHRS 4
- OPTN 3
- Target Price
- CHRS $6.13
- OPTN $3.00
- AVG Volume (30 Days)
- CHRS 3.1M
- OPTN 1.1M
- Earning Date
- CHRS 11-06-2024
- OPTN 11-12-2024
- Dividend Yield
- CHRS N/A
- OPTN N/A
- EPS Growth
- CHRS N/A
- OPTN N/A
- EPS
- CHRS N/A
- OPTN N/A
- Revenue
- CHRS $304,340,000.00
- OPTN $75,672,000.00
- Revenue This Year
- CHRS $3.33
- OPTN $24.44
- Revenue Next Year
- CHRS $16.77
- OPTN $49.00
- P/E Ratio
- CHRS N/A
- OPTN N/A
- Revenue Growth
- CHRS 44.19
- OPTN 5.13
- 52 Week Low
- CHRS $0.66
- OPTN $0.32
- 52 Week High
- CHRS $3.70
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- CHRS 69.14
- OPTN 24.29
- Support Level
- CHRS $0.70
- OPTN $0.66
- Resistance Level
- CHRS $0.89
- OPTN $0.81
- Average True Range (ATR)
- CHRS 0.10
- OPTN 0.07
- MACD
- CHRS 0.04
- OPTN -0.04
- Stochastic Oscillator
- CHRS 93.70
- OPTN 9.58
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.